…
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Genelux Corporation appears positioned as a clinical-stage biotechnology company focused on oncolytic viral immunotherapies targeting solid tumors. Its long-term growth drivers include clinical data readouts, potential regulatory approvals and strategic partnerships that could support commercialization, and investors may find the company attractive because successful clinical outcomes could validate the platform and create significant oncology assets.
Major investment risks include clinical trial failure, regulatory setbacks, limited revenue and cash runway, dilution from future financing and strong competition in oncology; investors should monitor execution and funding needs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -32.15M | -29.87M | -28.30M | -4.11M | -16.38M |
| Net income | -32.15M | -29.87M | -28.30M | -5.21M | -17.80M |
| Selling general administrative | 13.37M | 12.71M | 11.57M | 5.00M | 8.29M |
| Selling and marketing expenses | - | - | 1.02M | - | - |
| Gross profit | -0.57M | -0.90M | -0.85M | 11.07M | - |
| Reconciled depreciation | 0.57M | 0.90M | 1.06M | 0.97M | 0.90M |
| Ebit | -33.21M | -29.87M | -27.48M | -3.01M | -14.61M |
| Ebitda | -32.64M | -28.97M | -26.46M | -2.04M | -14.12M |
| Depreciation and amortization | 0.57M | 0.90M | 1.02M | 0.97M | 0.50M |
| Operating income | -33.21M | -31.70M | -24.16M | -3.01M | -14.61M |
| Other operating expenses | 33.22M | 31.70M | 24.34M | 14.08M | 14.61M |
| Interest expense | - | 0.00M | 3.97M | 1.41M | 1.42M |
| Tax provision | - | - | 0.00M | 1.10M | - |
| Interest income | 1.07M | 1.46M | 0.24M | - | - |
| Net interest income | 1.07M | 1.46M | -4.37M | -1.41M | -1.81M |
| Income tax expense | - | - | 0.85M | 1.10M | 1.42M |
| Total revenue | 0.01M | 0.01M | 0.17M | 11.07M | 0.00M |
| Total operating expenses | 32.65M | 30.80M | 23.32M | 14.08M | 14.61M |
| Cost of revenue | 0.57M | 0.90M | 1.02M | - | - |
| Total other income expense net | 1.07M | 1.83M | -4.13M | -1.09M | -1.76M |
| Net income from continuing ops | -32.15M | -29.87M | -25.02M | -5.21M | -16.38M |
| Net income applicable to common shares | - | - | - | -5.21M | -16.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19.03M | 34.72M | 27.89M | 5.53M | 8.13M |
| Other current assets | 0.54M | 0.65M | 1.01M | 1.50M | 1.33M |
| Total liab | 7.48M | 8.44M | 8.42M | 41.31M | 41.24M |
| Total stockholder equity | 11.54M | 26.27M | 19.47M | -35.78M | -33.11M |
| Deferred long term liab | - | - | - | 1.57M | - |
| Other current liab | 5.80M | 1.00M | 2.12M | 8.02M | 6.96M |
| Common stock | 0.04M | 0.04M | 0.03M | 0.01M | 0.01M |
| Capital stock | 0.04M | 0.04M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -283.54M | -251.39M | -221.52M | -189.78M | -184.58M |
| Other assets | - | - | - | - | 0.09M |
| Cash | 5.33M | 8.56M | 9.42M | 0.40M | 4.50M |
| Total current liabilities | 6.22M | 6.90M | 6.55M | 31.63M | 22.48M |
| Current deferred revenue | - | - | - | 0.17M | 4.50M |
| Net debt | -3.65M | -6.70M | -6.90M | 25.96M | 20.82M |
| Short term debt | 0.43M | 0.33M | 0.65M | 16.66M | 6.56M |
| Short long term debt | - | - | - | 16.40M | 6.16M |
| Short long term debt total | 1.69M | 1.87M | 2.52M | 26.35M | 25.31M |
| Other stockholder equity | 295.04M | 277.57M | 240.96M | 153.97M | 151.43M |
| Property plant equipment | - | - | - | - | 2.21M |
| Total current assets | 15.13M | 31.55M | 24.20M | 1.89M | 5.82M |
| Net tangible assets | - | - | - | - | -33.13M |
| Short term investments | 9.26M | 22.33M | 13.77M | - | - |
| Long term debt | - | - | - | 8.52M | 18.02M |
| Accounts payable | 4.36M | 5.57M | 3.78M | 6.78M | 4.46M |
| Accumulated other comprehensive income | 0.01M | 0.06M | 0.01M | 0.00M | 0.00M |
| Non currrent assets other | 0.14M | 0.09M | 0.09M | 1.66M | 0.09M |
| Non current assets total | 3.90M | 3.17M | 3.69M | 3.64M | 2.30M |
| Capital lease obligations | 1.69M | 1.87M | 2.52M | 1.43M | 1.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 13.24M | -8.13M | -0.78M | -0.05M | 0.00M |
| Change to liabilities | - | - | - | -4.33M | 5.25M |
| Total cashflows from investing activities | 12.14M | -8.13M | -14.72M | -0.05M | -0.05M |
| Net borrowings | - | 0.00M | 0.21M | - | -0.56M |
| Total cash from financing activities | 9.89M | 28.51M | 44.02M | -0.48M | -0.27M |
| Change to operating activities | - | - | - | - | -1.17M |
| Net income | -32.15M | -29.87M | -28.30M | -5.21M | -16.38M |
| Change in cash | -3.23M | -0.85M | 9.02M | -4.10M | -6.86M |
| Begin period cash flow | 8.56M | 9.42M | 0.40M | 4.50M | 11.35M |
| End period cash flow | 5.33M | 8.56M | 9.42M | 0.40M | 4.50M |
| Total cash from operating activities | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M |
| Issuance of capital stock | 9.66M | 27.82M | 39.65M | 0.00M | 0.14M |
| Depreciation | 0.24M | 0.90M | 1.02M | 0.97M | 0.90M |
| Other cashflows from financing activities | 9.89M | 0.69M | 4.16M | -0.47M | 1.08M |
| Change to netincome | - | - | - | 2.10M | 4.62M |
| Capital expenditures | 1.10M | 0.38M | 1.02M | 0.05M | 0.05M |
| Change in working capital | -1.05M | 0.75M | -3.28M | -1.69M | 4.08M |
| Stock based compensation | 5.87M | 6.07M | 5.20M | 2.42M | 4.27M |
| Other non cash items | 1.81M | 0.92M | 5.08M | -0.06M | 0.20M |
| Free cash flow | -26.37M | -21.61M | -21.30M | -3.62M | -6.58M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GNLX Genelux Corporation Common Stock |
-0.04 1.84% |
1.86 | - | - | 13969.50 | 7.15 | 12362.42 | -327.19 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
2625 Townsgate Road, Westlake Village, CA, United States, 91361
805 267 9889
25
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas Zindrick J.D. | Chairman, CEO & President | 1960 |
| Ms. Lourie S. Zak | Chief Financial Officer | 1964 |
| Ms. Caroline Jewett | VP & Head of Quality | 1965 |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer | 1957 |
| Mr. Sean Ryder J.D. | General Counsel & Corporate Secretary | 1970 |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development | 1972 |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer | 1946 |
| Mr. Ralph Smalling B.Sc. | VP & Head of Regulatory Affairs | 1957 |
| Mr. Thomas D. Zindrick J.D. | Chairman, CEO & President | 1960 |
| Mr. Matthew Pulisic M.B.A. | CFO and Principal Financial & Accounting Officer | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.